BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
2 Cui Y, Cui XD, Xu M, Fang M, Cai MJ. Serum apolipoprotein C3 levels are negatively associated with hepatitis B virus DNA in HBeAg-negative chronic hepatitis B patients. Lipids Health Dis 2019;18:138. [PMID: 31186008 DOI: 10.1186/s12944-019-1084-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Wang Y, Mei Y, Ao Z, Chen Y, Jiang Y, Chen X, Qi R, Fu B, Tang J, Fang M, You M, Zhang T, Yuan Q, Luo W, Xia N. A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105265] [Reference Citation Analysis]
4 Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther 2019;17:943-55. [PMID: 31738607 DOI: 10.1080/14787210.2019.1694906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Reference Citation Analysis]
6 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
7 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
8 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
9 Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, Carolo G. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021;11:2185. [DOI: 10.3390/diagnostics11122185] [Reference Citation Analysis]
10 Poortahmasebi V, Alavian SM, Ghaziasadi A, Azadi A, Nasiri Toosi M, Jazayeri SM. Detection and Quantification of Hepatitis B Virus Genomes in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B Virus Infection, Cirrhosis, and Hepatocellular Carcinoma Patients. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.120982] [Reference Citation Analysis]
11 Liu Y, Zhao ZH, Lv XQ, Tang YW, Cao M, Xiang Q, Wu Y, Zhang HT, Lai GQ. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models. J Med Virol 2020. [PMID: 32427358 DOI: 10.1002/jmv.26025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
13 Lin WL, Hung JH, Huang W. Association of the Hepatitis B Virus Large Surface Protein with Viral Infectivity and Endoplasmic Reticulum Stress-mediated Liver Carcinogenesis. Cells 2020;9:E2052. [PMID: 32911838 DOI: 10.3390/cells9092052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Laras A, Papatheodoridi M, Panopoulou E, Papatheodoridis GV, Hadziyannis SJ, Hadziyannis E. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B. Virol J 2022;19. [DOI: 10.1186/s12985-022-01749-7] [Reference Citation Analysis]
15 Elizalde MM, Tadey L, Mammana L, Quarleri JF, Campos RH, Flichman DM. Biological Characterization of Hepatitis B virus Genotypes: Their Role in Viral Replication and Antigen Expression. Front Microbiol 2021;12:758613. [PMID: 34803982 DOI: 10.3389/fmicb.2021.758613] [Reference Citation Analysis]
16 Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Su CW, Wu CY, Lin JT, Ho HJ, Wu JC. Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B. J Chin Med Assoc 2020;83:125-33. [PMID: 32015266 DOI: 10.1097/JCMA.0000000000000247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Huang X, Zheng X, Shen C. Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus. Evid Based Complement Alternat Med 2021;2021:2884151. [PMID: 34764998 DOI: 10.1155/2021/2884151] [Reference Citation Analysis]
22 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 7.3] [Reference Citation Analysis]
23 Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2019;26:1481-8. [PMID: 31446638 DOI: 10.1111/jvh.13195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
24 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
27 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
28 Li Z, Ma L, Di L, Lin X. MicroRNA‑1271‑5p alleviates the malignant development of hepatitis B virus‑mediated liver cancer via binding to AQP5. Mol Med Rep 2021;23:386. [PMID: 33760167 DOI: 10.3892/mmr.2021.12025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Senoymak MC, Ozkan H. Evaluation of the Relationship between Insulin Resistance and HBV DNA Level in Patients with HBeAg-negative Chronic HBV Infection (Natural Course Phase 3). Euroasian J Hepatogastroenterol 2020;10:85-91. [PMID: 33511070 DOI: 10.5005/jp-journals-10018-1329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Koyaweda GW, Ongus JR, Machuka E, Juma J, Macharia R, Komas NP, Pelle R. Detection of circulating hepatitis B virus immune escape and polymerase mutants among HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic. Int J Infect Dis 2020;90:138-44. [PMID: 31682960 DOI: 10.1016/j.ijid.2019.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]